The Competition in the MASH Intensifies with the Unexpected Arrival of GLP-1

The medical landscape around MASH (metabolic-associated steatoh hepatitis) is undergoing an unexpected transformation that is disrupting treatment strategies. Until recently, research was marked by numerous failures and timid advances, but the arrival of GLP-1 agonists (glucagon-like peptide-1) injects new life into this fierce competition. This major turning point heralds an intensification of competition among pharmaceutical players while opening new perspectives for the management of this chronic disease, whose prevalence continues to rise globally.

More than 250 million patients are affected by MASH, a condition that threatens to double its advanced cases by 2030 due to underlying disorders such as obesity and metabolic syndrome. After several years of stagnation in the development of effective treatments, 2024 and 2025 are marked by a series of FDA and EMA approvals, including that of Rezdiffra and Wegovy, which embody a real medical innovation in the field. These newcomers intensify competition and reposition pharmacology at the center of discussions, with significant commercial and therapeutic stakes.

At the heart of this dynamic, the race against time among pharmaceutical and biotech laboratories is intensifying, gradually transforming medical care. While some focus on various agonists and analogs like GLP-1, others explore innovative pathways such as FGF21 analogs or agents targeting liver fibrosis. The global MASH market, estimated at $7.9 billion in 2024, could reach nearly $32 billion by 2033, dramatically illustrating the intensity of industrial competition as well as the growing hope surrounding these promising treatments.

MASH: A Major Medical Challenge Requiring Accelerated Pharmacological Innovation

MASH, an advanced form of non-alcoholic fatty liver disease, is characterized by liver inflammation associated with fat infiltration amplified by metabolic dysfunction. This disorder currently affects more than a quarter of a billion people worldwide, making it an urgent public health issue.

This diagnosis relies on various criteria, including clinical examination and biological tests aimed at detecting inflammation and fibrosis. The complexity of MASH arises from its close links with metabolic pathologies such as obesity, type 2 diabetes, and sleep apnea. Their increasing prevalence amplifies the constant rise in patient numbers.

Traditional management primarily involved strict nutritional management, regular physical activity, and monitoring of liver parameters. However, the failures of numerous pharmacological agents in clinical trials related to inhibitors or agonists targeting different receptors, such as those from Genfit, Gilead, or Novartis, have indicated the need for truly innovative approaches.

• Treatments such as elafibranor (PPAR agonist) and obeticholic acid (FXR agonist) failed to demonstrate lasting benefits in Phase III.

• Previous therapies did not effectively address liver fibrosis or the reduction of lipid deposits in the liver.

• The lack of drug options had weakened clinical management, relying primarily on lifestyle changes.

Faced with these clinical imperatives, the emergence of GLP-1, agents that are both metabolic and anti-inflammatory, has sparked growing interest among biopharma companies. Their mechanism of action aims to improve insulin sensitivity, reduce steatosis, and protect the liver from more severe damage. This innovation is all the more crucial as the number of severe cases is expected to double by 2030, anticipating a real surge in therapeutic demand.

In line with this necessity, the launch of Rezdiffra in 2024 through FDA authorization represents a significant advancement. This drug, a selective β-thyroid receptor agonist, has filled a substantial part of the therapeutic void. At the same time, the authorization of Wegovy, an injectable GLP-1 agonist from Novo Nordisk in 2025, marks an unexpected arrival in MASH medicine and reignites the competition for better health management related to this disease.

GLP-1 and Their Revolutionary Impact on MASH Treatment

GLP-1 agonists, such as Wegovy, represent a therapeutic category that combines metabolic management, inflammation, and liver fibrosis. These molecules mimic a natural hormone involved in regulating blood sugar and appetite and have shown promising results in weight reduction and improvement of liver function.

Their mechanism relies on the activation of GLP-1 receptors that promote insulin secretion, thereby slowing the accumulation of fat in the liver while reducing oxidative stress and inflammation. Their prolonged efficacy, combined with an adapted diet and physical exercise, thus opens a new era in the pharmacology of MASH.

• Wegovy: subcutaneous injection approved for patients with moderate fibrosis without cirrhosis

• Rezdiffra: oral treatment targeting advanced liver fibrosis

• Zepbound (tirzepatide) awaiting approval, combining GLP-1 and GIP inhibitor

• Survodutide, dual glucagon-GLP-1 agonist, in advanced clinical trials

• Efimosfermin, FGF21 analog, a new promising avenue in the fight against MASH

The practical implications of these treatments have a profound impact in clinical settings. Where in the past, options were limited to rigorous follow-up without real medicinal action, these innovative solutions now allow for:

• A more effective control of the disease progression.

• The reduction of fibrosis, the main cause of severe complications.

• A better life prognosis with measurable improvement in liver conditions.

Data from ESSENCE trials for Wegovy have demonstrated a significant improvement in the resolution of steatohepatitis without worsening fibrosis, a new promise in the field. This progress has indeed prompted an unprecedented intensification of competition among laboratories to improve formulas, administration, and product tolerability.

The Key Players and the Rise of Competition in MASH Pharmacology

With the initiation of new treatments, the MASH market has become a true arena for strategic competition among major pharmaceutical companies and innovative biotechnologies. Novo Nordisk stands out today with Wegovy, while Madrigal Pharmaceuticals bets on Rezdiffra as a pioneer in oral treatment. This duality reveals a marked commercial challenge that drives continuous innovation.

Beyond these two players, the race is expanding with laboratories like Eli Lilly, which is developing Zepbound, and Boehringer Ingelheim associated with Zealand Pharma for Survodutide, a dual agonist in development with positive results. GSK is also investing heavily following the acquisition of efimosfermin, an FGF21 analog planned for monthly administration.

• Investments exceeding a billion dollars to accelerate trials and market entry

• Collaboration between large firms and innovative biotech to complete therapeutic portfolios

• Multiplication of clinical trials targeting different stages of MASH

• Research focused on safety, tolerability, and ease of administration

• Parallel development of diagnostic tools to better target patients

Meanwhile, several European companies such as Inventiva, Enyo Pharma, and Zealand Pharma are focusing on innovative molecules such as pan-PPAR agonists or FXR agonists, thereby expanding the therapeutic arsenal. These organizations energize a local economy while providing recognized expertise, a mark of trust for patients.

This fierce competition not only stimulates the development of new medications but also gives a renewed impetus to research on the overall health management related to MASH. By facilitating early diagnosis and treatment, these collective efforts improve the quality of life for patients and reduce costs associated with severe complications of the disease.

Diagnosis and Treatment: Innovations for Proactive Management of MASH

The success of new therapies closely depends on accurate and early diagnosis. Recent efforts have focused on developing non-invasive biomarkers capable of assessing the severity of fatty liver and associated fibrosis. For instance, the French company Genfit offers in vitro tests NIS4+ and NIS2+, while Nordic Bioscience targets specific collagen fragments, revolutionizing the identification of high-risk patients.

This diagnostic advancement is part of a holistic approach where pharmacology does not improvise alone, but complements a multidisciplinary strategy integrating nutrition, physical activity, and enhanced medical follow-up. The arrival of GLP-1 in this framework improves the overall effectiveness of treatment and drives medicine towards unprecedented personalization.

• Non-invasive tests to detect early signs of MASH

• Combined strategies with medications and lifestyle changes

• Better segmentation of patients according to the degree of fibrosis

• Personalized follow-up to adjust treatments over time

• Strengthened collaboration between specialists and laboratories

Thanks to this synergy between pharmacological innovation and efficient diagnostics, the management of MASH is moving towards a more dynamic and responsive model. This reduces the risk of severe complications such as cirrhosis or hepatocellular carcinoma, which require heavy interventions. Thus, medicine gains in efficiency, benefiting from enhanced coordination between prevention and treatment.

Future Perspectives: Towards Greater Integration of GLP-1 and Other Innovations in MASH Management

As laboratories continue to expand their portfolios, competition intensifies on several fronts. The arrival of injectable treatments like Wegovy on the market upends conventions and paves the way for innovations in terms of administration, therapeutic combinations, and patient centricity.

Simultaneously, research on hybrid analogs combining GLP-1 and other peptides, or multi-target saving solutions, is drawing attention. The emergence of molecules such as Zepbound or Survodutide demonstrates a collective willingness to improve efficacy without compromising tolerability.

• Development of therapies combining multiple mechanisms of action

• Improvement of protocols to minimize side effects

• Use of biomedical data to tailor personalized treatments

• Potential extension of indications to other metabolic diseases

• Strengthening public-private cooperation in clinical research

The MASH market is expected to grow exponentially, representing a significant economic engine in the pharmaceutical sector. However, this progression must be accompanied by increased vigilance regarding the safety, profitability, and accessibility of these solutions. Indeed, the fight against this disease also involves civic engagement and awareness for prevention to curb the epidemic.

To better understand how this dynamic is also reflected in other sectors, notably the vintage motorcycle industry, readers can consult tests and news from the brand Mash, reflecting intense competition in another field but with similar stakes in innovation and performance: Essais Mash, Mash Corsica Tour, and Moto Mash Seventy 125.